Medicine for treating kidney cancer are FDA approved

Medications for treating kidney cancer (1)

Index-china lists cancer treatment drugs approved by the US Food and Drug Administration (FDA) for kidney cancer.

The list includes generic names and brand names. The name of the drug links to the information about medicines to treat kidney cancer of Index-china. There may be drugs used in kidney cancer not listed here.

The drug is approved for the treatment of kidney cancer

1. Afinitor ( Everolimus )

Everolimus is approved to treat:

  • Breast cancer: It is used in combination with exemestane in postmenopausal women with positive hormone receptor (HR +) negative HER2 (HER2-) negative disease and does not get better after letrozole treatment. or anastrozole.
  • Pancreatic cancer, gastric cancer and lung cancer: It is used in adults with advanced neurological tumors that cannot be removed with locally advanced or metastatic surgery.
  • Renal cell carcinoma has progressed: in adults who do not respond to treatment with sunitinib or sorafenib.
  • Giant cell adenocarcinoma in adults and children 1 year of age and older with tuberous sclerosis and inoperable.

The use of Everolimus to treat cancer is approved for the brands Afinitor and Afinitor Disperz .

Everolimus is also approved to treat graft rejection, this use is approved for the Zortress brand .

Afinitor 10mg Everolimus antagonist medication (1)
Afinitor 10mg Everolimus antagonist medication (1)

2. Avastin (Bevacizumab)

Bevacizumab is approved for use alone or with other drugs to treat:

Cervical cancer: did not respond to treatment with other treatments, metastatic or recurrent. It is used in combination with Paclitaxel and Cisplatin or Topotecan hydrochloride , which is approved for both the Bevacizumab brand of Avastin and Mvasi .

Metastatic colorectal cancer: It is used in combination with other drugs, the use of which is approved for both Bevacizumab brand of Avastin and Mvasi .

Glioblastoma (a type of brain cancer), it is used in adults with:

  • Cancer has recurred: this use was approved for Avastin ‘s Bevacizumab brand .
  • Cancer gets worse after other treatments: this use is approved for Mvasi ‘s Bevacizumab brand .

Nonsquamous advanced non-small cell lung cancer locally: cannot be removed by surgery, metastases or recurrences. It is used in combination with Carboplatin and Paclitaxel , which is approved for both Bevacizumab brands of Avastin and Mvasi .

Ovarian epithelium, fallopian tube or primary peritoneal cancer: It is used in patients with stage III, stage IV or recurrent disease. This use is approved for Avastin ‘s Bevacizumab trademark .

Metastatic renal cell carcinoma: It is used in combination with alpha interferon, which is approved for both the Bevacizumab brand of Avastin and Mvasi .

3. Inlyta (Aciditib)

Axitinib is approved to treat:

  • Advanced renal cell carcinoma: It is used in patients who no longer respond to treatment when receiving other chemotherapy.

Axitinib is also being studied in the treatment of other types of cancer.

Inlyta Medicine 1mg 5mg Acid Antitinib Anticoagulant (3)
Inlyta Medicine 1mg 5mg Acid Antitinib Anticoagulant (3)

4. Yervoy (Ipilimumab)

Ipilimumab is approved to treat:

Colorectal cancer in adults and children 12 years of age and older: It is used with nivolumab to treat micro-unstable cancer (MSI-H) or inadequate repair of cancer (dMMR) worsened after treatment with fluoropyrimidine, oxaliplatin and irinotecan hydrochloride. This use is approved under the FDA’s Acceleration Approval Program.

Melanoma

  • Ipilimumab is used as adjuvant therapy in patients with surgical melanoma and lymph nodes.
  • Ipilimumab is used in adults and children 12 years of age and older whose disease cannot be removed by surgery or has spread.

Renal cell carcinoma: It is used in combination with Nivolumab in some untreated renal cell carcinoma patients.

Yervoy medicine 5mg ml Ipilimumab treatment of skin cancer (1)
Yervoy medicine 5mg ml Ipilimumab treatment of skin cancer (1)

5. Sutent (Sunitinib)

Sunitinib is approved to treat:

  • Gastrointestinal stromal tumor (a type of gastric cancer): It is used in patients whose condition has worsened with Imatinib mesylate or who cannot use it.
  • Pancreatic cancer: It is used in patients with advanced neurological tumors that cannot be removed with surgery, local progression, or metastases.
  • Renal cell carcinoma: It is used In patients with advanced disease. It is also adjuvant therapy in adults who have had kidney resection and have a high risk of cancer coming back.
Sutent 12 5mg Sunitinib anti-inflammatory drug (5)
Sutent 12 5mg Sunitinib anti-inflammatory drug (5)

6. Votrient (Pazopanib)

Pazopanib is approved for treatment:

  • Advanced renal cell carcinoma (a type of kidney cancer)
  • Soft tissue sarcomas that are advanced : It is used in patients who have been treated with chemotherapy.

Pazopanib hydrochloride is also being studied in the treatment of other cancers.

Votrient medicine 200mg 400mg Pazopanib anticoagulant treatment (3)
Votrient medicine 200mg 400mg Pazopanib anticoagulant treatment (3)

7. Opdivo (Nivolumab)

Nivolumab is approved for use alone or with other drugs to treat:

Classic Hodgkin lymphoma in adults with recurrent or worsening disease:

  • Autologous stem cell transplant and treatment with vedotin brentuximab
  • Use at least three other types of treatment including autologous stem cell transplant.

Colorectal cancer in adults and children 12 years of age and older: It is used alone or with Ipilimumab for the treatment of micro-unstable cancer (MSI-H) or inadequate repair of cancer. (dMMR) gets worse after treatment with fluoropyrimidine, oxaliplatin and irinotecan hydrochloride.

Hepatocellular carcinoma: It is used in patients who have been treated with sorafenib.

Malignant tumor, it is used:

In patients who have a disease that cannot be surgically removed or have metastasized, it is sometimes used in combination with Ipilimumab .

  • In patients who have had surgery to remove the malignant tumor that has spread to the lymph nodes or has spread.

Metastatic non-small cell lung cancer : It is used in patients with more severe illness during or after platinum chemotherapy. Cancer patients with certain gene mutations should only receive Nivolumab if their disease becomes worse after treatment with FDA-approved therapy for gene mutations.

Advanced renal cell carcinoma , it is used:

  • In patients who have been treated with drugs that inhibit angiogenesis.
  • Combined treatment with Ipilimumab in some untreated renal cell carcinoma patients.

Metastatic small cell lung cancer: it is used in patients with more severe illness after platinum chemotherapy and at least one other therapy.

Squamous cell carcinoma of the head and neck has metastasized or recurred: in patients with more severe disease during or after platinum chemotherapy.

Urinary carcinoma (a type of bladder cancer) that has progressed locally or has spread: It is used in patients with more severe illness during or after platinum chemotherapy.

The use of Nivolumab is approved under the FDA’s accelerated approval program. As an approved condition, a confirmation trial must show that Nivolumab has clinical benefits in these patients.

8. Nexavar (Sorafenib)

Sorafenib is approved to treat:

  • Hepatocellular carcinoma cannot be removed with surgery.
  • Advanced renal cell carcinoma .
  • Thyroid cancer in some patients with advanced, recurrent or metastatic disease does not respond to radioactive iodine therapy.

Sorafenib is also being studied in the treatment of other types of cancer.

Nexavar medicine 200mg antidote for liver cancer treatment (1)
Nexavar medicine 200mg antidote for liver cancer treatment (1)

9. Lenvima (Lenvatinib)

Lenvatinib is approved for use alone or with other drugs to treat:

  • Endometrial cancer is advanced and worsens after using other treatments. It is used in combination with Pembrolizumab in patients with unstable -high microscopic cancer (MSI-H) or inadequate repair (dMMR) and cannot be treated with surgery or radiotherapy. .
  • Hepatocellular carcinoma : it is used as first-line treatment in patients with diseases that cannot be removed with surgery.
  • Advanced renal cell carcinoma : It is used in combination with Everolimus in patients who have been treated with drugs that inhibit angiogenesis.
  • Thyroid cancer in some patients with advanced, recurrent or metastatic disease does not respond to radioactive iodine therapy.

This use is approved under the FDA’s accelerated approval program. As an approval condition, validation trials must show that Lenvatinib has clinical benefits in these patients.

Lenvima 4mg 10mg Lenvatinib for treating liver cancer (1)
Lenvima 4mg 10mg Lenvatinib for treating liver cancer (1)

10. Keytruda (Pembrolizumab)

Pembrolizumab is approved for treatment:

Cervical cancer recurrence or metastasis: It is used in patients with cancer protein PD-L1va sicker during or after chemotherapy.

Endometrial cancer is advanced and worsens after systemic therapies. It is used in combination with Lenvatinib in patients with unstable cancer using a high-microscope (MSI-H) or inadequate repair (dMMR) and cannot be treated with surgery or radiation therapy. .

Stomach cancer or regular gastric junction cancer and either locally advanced or metastatic. It is used in cancer patients who have PD-L1 protein and get worse during or after two or more types of treatment including fluoropyrimidine and platinum chemotherapy and, in some cases, targeted therapies. pepper HER2.

Hepatocellular carcinoma in patients who have been treated with Sorafenib.

Hodgkin’s lymphoma in adults and children: it is used in patients who do not respond to treatment or have relapsed after at least three other types of treatment.

Malignant tumor , it is used in:

  • Patients with cancer cannot be removed surgically or have metastasized.
  • The patient had surgery to remove the cancer that has spread to the lymph nodes.

Merkel cell carcinoma in adults and children: it is used in patients with locally recurrent and metastatic or metastatic disease.

-High instability Microsatellite (MSI-H) or cancer-inappropriate inappropriate repair (dMMR) that is metastatic and cannot be removed by surgery. It is used in adults and children to:

  • Solid tumors have become worse after other treatments or cannot be treated with other treatments.
  • Colorectal cancer has become worse after treatment with fluoropyrimidine, oxaliplatin and irinotecan hydrochloride.
  • MSI-H and dMMR can have certain gene mutations and may not respond to certain types of treatment.

Non-small cell lung cancer has spread, it is used:

  • Combining treatment with pemetrexed and platinum chemotherapy as first-line treatment in asymptomatic patients without EGFR or ALK gene mutations.
  • Combined treatment with carboplatin and either paclitaxel or paclitaxel stabilizes the nanoparticle formulation as first-line treatment for scab.
  • First-line treatment in patients with stage III disease with PD-L1 protein and no EGFR or ALK gene mutations. It is used in cancer patients who cannot be treated with surgery, chemotherapy or radiation.
  • Alone in patients with cancer who have PD-L1 protein and get worse during or after platinum chemotherapy. Patients with cancer that have the EGFR or ALK gene mutation should only use pembrolizumab if their disease gets worse after FDA-approved therapy for these mutations.

Primary primary mediastinal lymphoma : it is used in adults and children with intractable disease or who have relapsed after at least two other therapies.

Advanced renal cell carcinoma: it is used with acidinib as first-line therapy.

Metastatic small cell lung cancer: it is used in patients with more severe illness during or after platinum chemotherapy and at least one other therapy.

Squamous cell carcinoma of the esophagus recurs, locally progresses, or metastases. It is used in patients with tumors that have PD-L1 protein and more severe disease after systemic therapy.

Squamous cell carcinoma in the head and neck has metastasized or recurrent: it is used:

  • Combining treatment with platinum and fluorouracil chemotherapy is a first-line treatment in patients who are unable to undergo surgery.
  • First-hand treatment in patients with unresectable surgical diseases and tumors with the PD-L1 protein.
  • Alone in patients with more severe illness during or after platinum chemotherapy.

Urothelial cancer has progressed locally or has spread, it is used in:

  • Cancer patients have the PD-L1 protein and cannot be treated with cisplatin.
  • Patients with cancer who cannot be treated with platinum chemotherapy or have become worse during or after platinum chemotherapy .¹

This use is approved under the FDA’s Acceleration Approval Program. As an approved condition, validation trials must show that Pembrolizumab has clinical benefits in these patients.

Keytruda 100mg 4ml Pembrolizumab Anticholinergic Treatment (4)
Keytruda 100mg 4ml Pembrolizumab Anticholinergic Treatment (4)

11. Proleukin (Aldesleukin)

Aldesleukin is approved for treatment:

  • Malignant tumors have metastasized
  • Kidney cell carcinoma has spread

Aldesleukin is also known as Interleukin-2 (IL-2).

12. Bavariaencio (Avelumab)

Avelumab is approved to treat:

  • Merkel cell cancer has metastasized: it is used in adults and children 12 years of age and older.
  • Advanced renal cell carcinoma . It is used with acidinib as first-line therapy.
  • Urinary carcinoma is locally or metastasized: it is used in patients with more severe illness during or after platinum chemotherapy.

These uses are approved under the FDA’s accelerated approval program. As a condition of approval, validation trials must show that Avelumab has clinical benefits in these patients.

13. Cabometyx (Cabozantinib-S-Malate)

Cabozantinib-s-malate is approved to treat:

  • Hepatocellular carcinoma: it is used in patients who have been treated with sorafenib, which is approved for the Cabometantx brand of Cabozantinib-s-malate.
  • Medullary thyroid cancer means progressive and metastatic: this use is approved for the Cometriq brand of cabozantinib-s-malate.
  • Advanced renal cell carcinoma : This use is approved for the Cabometantx brand of Cabozantinib-s-malate.

14. Torisel (Temsirolimus)

Temsirolimus is approved for treatment:

  • Advanced renal cell carcinoma .

Temsirolimus is also being studied in the treatment of other types of cancer.

Medications for treating kidney cancer (2)
Medications for treating kidney cancer (2)

Please COMMENT below for our answers to FDA-approved kidney cancer medications

Note: The article information about the FDA approved kidney cancer treatment drug for the purpose of sharing knowledge is for reference only, the patient is not allowed to use the drug on his own, all information on drug use must be followed only specialist physician.

Source Reference medicine for treating kidney cancer:

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.